Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC

Trial Details

NCT ID
NCT06995677
Phase
PHASE2
Sponsor
Tyra Biosciences, Inc
Status
RECRUITING
Cancer Type
Non-Muscle-Invasive Bladder Cancer
Interventions
  • TYRA-300 60mg
  • TYRA-300 50mg
  • TYRA-300 Dose TBD
Locations (sample)
  • Homewood, Alabama, United States|33.47177,-86.80082
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Murrieta, California, United States|33.55391,-117.21392
  • San Diego, California, United States|32.71571,-117.16472
  • Chicago Ridge, Illinois, United States|41.70142,-87.77922

Key Eligibility Criteria

  • Participants age 18 and over of informed consent and willing and able to comply with all requires study procedures
  • Able to understand and given written informed consent
  • Participants with histologically confirmed low-grade NMIBC within 6 weeks prior to randomization with prior diagnostic biopsy/TURBT to confirm stag…
  • Ta low grade

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →